Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Stock Rating Upgraded by Barclays

Barclays upgraded shares of Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) to a strong sell rating in a research report sent to investors on Tuesday, Zacks.com reports.

Separately, Royal Bank of Canada upgraded shares of Recordati Industria Chimica e Farmaceutica to a “hold” rating in a report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Stock Performance

OTCMKTS RCDTF opened at $52.25 on Tuesday. Recordati Industria Chimica e Farmaceutica has a 1 year low of $52.25 and a 1 year high of $52.25. The business’s fifty day moving average is $52.25 and its two-hundred day moving average is $51.87. The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.73.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last announced its earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter. Recordati Industria Chimica e Farmaceutica had a return on equity of 30.78% and a net margin of 17.41%. The company had revenue of $622.00 million for the quarter.

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.